Pediatric Plan (US PSP / EU PIP) — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The pediatric development plan — the US Pediatric Study Plan (PSP) and the EU Paediatric Investigation Plan (PIP).
Why it exists. Both the FDA and EMA require sponsors to plan (or justify deferral/waiver of) studies in children early in development. The plan states what pediatric studies will be done, or why they are not needed, for GLPI-103.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. FDA PREA/PSP; EU Paediatric Regulation (PIP)
Pediatric Plan (US PSP / EU PIP) — GLPI-103
| Field | Value |
|---|---|
| Document ID | PED-001 |
| Version | 1.0 |
| Standard | FDA PREA/PSP; EU Paediatric Regulation (PIP) |
| Confidentiality | Confidential — portfolio use |
Combined summary of the US Pediatric Study Plan (PSP) and EU Paediatric Investigation Plan (PIP) required for the marketing application.
[MOCK].
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Regulatory | Initial pediatric plan |
1. Condition & Relevance
Type 2 diabetes mellitus occurs in adolescents; a pediatric development plan is required (or a waiver/deferral justified) for the new active substance.
2. Proposed Approach
- Deferral of pediatric studies until adult efficacy/safety is established (pivotal GLPI103-301 complete).
- Planned adolescent (10–<18 y) study of efficacy/safety/PK with appropriate formulation; pediatric PK modeling and extrapolation where scientifically justified.
- Waiver proposed for children below the age where T2DM is not relevant.
3. Regulatory Interactions
PSP agreed with FDA (PREA); PIP agreed with the EMA Paediatric Committee (PDCO), including key binding measures and timelines. Updates submitted as the program matures.
Comments (0)
No comments yet. Be the first to say something!